8-K current report · filed Aug 4, 2026

Niagen Bioscience, Inc. (NAGE) 8-K Current Report: August 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2NAGE overview

Short answer

Niagen Bioscience, Inc. (NAGE) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Earnings release covers quarter ended June 30, 2026.

Niagen Bioscience, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Earnings release covers quarter ended June 30, 2026
  • Exhibit 99.1 contains Niagen Bioscience’s reported quarterly financial results

Item 7.01 · Regulation FD Disclosure

  • Corporate presentation released August 4, 2026, providing updated company information to investors
  • Exhibit 99.2 contains the presentation, including any strategic, operational, or financial updates disclosed by Niagen Bioscience

Item EX-99.1 · Exhibit EX-99.1

  • Q2 sales $29.8M, down from $31.1M; Tru Niagen contributed $24.2M while direct-to-consumer sales grew 23% year-over-year
  • Gross margin 64.8%; operating income fell to $0.7M from $3.2M as operating expenses increased to $18.6M
  • Net income $1.0M versus $3.6M; adjusted EBITDA $3.0M versus $5.0M, signaling weaker underlying profitability
  • Cash from operations $1.6M year-to-date and cash $66.7M; $2.8M stock repurchase during the quarter
  • NB4168 received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations, adding long-term pharmaceutical optionality with preclinical studies planned for Q3 2026

Item EX-99.2 · Exhibit EX-99.2

  • Q2 net sales $29.8M, down from $31.1M, while Tru Niagen sales rose to $24.2M from $22.7M
  • Gross margin 64.8%, net income $1.0M, diluted EPS $0.01, and Adjusted EBITDA $3.0M
  • Cash $66.7M with no borrowings, supporting investment in telehealth, skincare, and pharmaceutical development
  • E-commerce sales $20.5M, up from $18.1M, while Niagen Ingredients declined to $5.4M from $7.4M
  • Strategic expansion: telehealth launch, Olympia Pharmaceuticals 503B partnership, Nanocloud skincare launch, and NB4168 therapeutic candidate disclosed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Niagen Bioscience, Inc. 8-K filings

Get the next NAGE 8-K as it lands

Follow NAGE for push alerts, or ask the research agent what this filing means.